Cytophage Technologies (TSXV:CYTO) Minority Interest : C$0.00 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Cytophage Technologies's minority interest for the quarter that ended in Mar. 2024 was C$0.00 Mil.

Cytophage Technologies Minority Interest Historical Data

The historical data trend for Cytophage Technologies's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Minority Interest Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Minority Interest

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Minority Interest	Get a 7-Day Free Trial			-	-	-	-	-

Cytophage Technologies Minority Interest Calculation

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.